Tri-calcium phosphate ceramics and allografts as bone substitutes for spinal fusion in idiopathic scoliosis as bone substitutes for spinal fusion in idiopathic scoliosis: comparative clinical results at four years.
The authors present the results of a comparative study of two series of posterolateral arthrodeses for scoliosis performed using COTREL DUBOUSSET instrumentation. Fifty-four consecutive patients underwent surgery for idiopathic scoliosis using the same technique. Thirty received a graft consisting of a mixture of corticocancellous autologous and allogenic bone frozen at -80 degrees, and 24 patients were grafted with a mixture of cortico-cancellous autologous bone and sticks of tricalcium phosphate (TCP, Biosorb, SBM, Lourdes, France). All patients were seen at three, six and twelve months, then once a year for at least four years with clinical and radiological evaluation at each visit. At the final follow up visit, no radiologic signs of pseudoarthrosis were found in either group with a minimum follow-up of 4 years. The appearance of bone callus was considered satisfactory at 6 months in all cases; moreover callus seemed to be more important in the TCP series, although this assessment was subjective. TCP resorption was total after 2 years, while allograft fragments were visible on x-rays after 2 years. Minor mechanical complications occurred but did not influence the results. Loss of correction was 8% of that initially obtained in the allograft group and 2% in the TCP group. Loss of correction did not progress after 6 months in the TCP group and after 2 years in the allograft group. Based upon this experience, the use of synthetic bone substitutes such as TCP would appear to be a valuable alternative to allografts in posterolateral spinal arthrodesis for idiopathic scoliosis, and it would eliminate the risk of viral contamination inherent to allograft implantation. To our knowledge, there have been no previous comparative studies concerning the use of tricalcium phosphate versus allograft in the literature.
Le Huec
J C
JC
Département d'Orthopédie, CHU Pellegrin Tripode, Bordeaux, France.
Lesprit
E
E
Delavigne
C
C
Clement
D
D
Chauveaux
D
D
Le Rebeller
A
A
D000293:Adolescent; D000328:Adult; D001673:Biodegradation, Environmental; D018786:Bone Substitutes / Q000737:chemistry / Q000627:therapeutic use*; D016025:Bone Transplantation / Q000009:adverse effects / Q000000981:diagnostic imaging / Q000379:methods*; D002146:Bony Callus / Q000000981:diagnostic imaging; D002130:Calcium Phosphates / Q000737:chemistry / Q000627:therapeutic use*; D002516:Ceramics / Q000737:chemistry / Q000627:therapeutic use*; D015925:Cryopreservation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010149:Postoperative Pain / Q000209:etiology; D011542:Pseudarthrosis / Q000517:prevention & control; D011859:Radiography; D012008:Recurrence; D012307:Risk Factors; D012600:Scoliosis / Q000000981:diagnostic imaging / Q000601:surgery*; D013123:Spinal Fusion / Q000295:instrumentation / Q000379:methods*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014777:Virus Diseases / Q000635:transmission
D018786:Bone Substitutes; D002130:Calcium Phosphates; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous